Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Cern scientists restart hunt for answers to mysteries of universe
    • UK mortgage rates rise at fastest pace in a decade
    • Eurozone inflation hits record 8.6% in June
    • Omicron variants drive 34% jump in England’s Covid infections
    • Biden administration floats new oil leasing plan in Gulf of Mexico
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • US government bonds rally after factory data heighten recession fears
    • Google closes data loophole amid privacy fears over abortion ruling
    • Central banks look to China’s renminbi to diversify foreign currency reserves
    • Biden administration floats new oil leasing plan in Gulf of Mexico
    • US Supreme Court’s blockbuster term reverberates through America
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Klarna valuation crashes to $6.5bn from $46bn
    • Ryanair chief warns fares will rise for 5 years because flying is ‘too cheap’
    • Boots left in limbo as bids fail to emerge
    • Covid could not sink cruise lines — but they now face an iceberg of debt
    • Vatican suffers £100mn-plus loss on Knightsbridge office sale
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Klarna valuation crashes to $6.5bn from $46bn
    • US government bonds rally after factory data heighten recession fears
    • A soft landing is becoming a distant dream
    • Live news updates from July 1: Crypto in focus as FTX buys BlockFi and Voyager Digital halts trading, Eurozone inflation hits record
    • The looming risks in private equity returns
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • The end of the frictionless life
    • A soft landing is becoming a distant dream
    • Time to change my subscription model
    • Mukesh Ambani: India’s top businessman starts succession planning
    • We may not agree with the Taliban but we should help Afghanistan
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • How can I move from being a specialist police detective to financial services?
    • What’s a good (and bad) way to leave your job?
    • If you want to be more likeable, try showing more stress
    • ‘Exactly how much virtue do you really want to signal?’
    • JSR’s Eric Johnson: ‘I encourage people to tell me exactly how they think’
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Serhii Plokhy: Putin’s imperialist narrative ‘is being crushed’
    • Life on the idyllic Swedish island where WW3 could start
    • The end of the frictionless life
    • Have we had enough of the nanny employer?
    • Time to change my subscription model
  • HTSI
  1. Companies
  2. Health
  3. Pharmaceuticals
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

Pharmaceuticals sector

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Friday, 1 July, 2022
    LexHealth Care
    Walgreens: without a sale of Boots, US group needs a health check Premium content

    Owning physical drugstores is not the cash cow it once was

  • Friday, 1 July, 2022
    Covid-19 vaccines
    Oxford BioMedica extends Covid vaccine deal with AstraZeneca

    New three-year contract in place if UK drugmaker continues to manufacture the jab

  • Thursday, 30 June, 2022
    Hedge funds
    Hedge funds scoop up biotech stocks after ‘catastrophic’ declines

    Some managers expect cheaper valuations will fuel M&A activity

  • Tuesday, 28 June, 2022
    Covid-19 vaccines
    FDA panel recommends redesigning Covid vaccine to target Omicron variant

    Change would incorporate genetic material from fast-spreading strain in new boosters

  • Tuesday, 28 June, 2022
    Anjana Ahuja
    Monkeypox makes pledges of pandemic solidarity look hollow

    The global south has once again been abandoned in its quest for vaccines

  • Monday, 27 June, 2022
    Croda International PLC
    US government to invest up to $75mn in new Croda factory

    Washington seeks to expand domestic production of crucial component of mRNA vaccines

  • Monday, 27 June, 2022
    Covid-19 vaccines
    Pause in medication would improve Covid jab response for millions, study shows

    Short break in immune suppression treatment improves antibody production after vaccination while doing little harm

  • Saturday, 25 June, 2022
    Covid-19 vaccines
    BioNTech/Pfizer say Omicron-targeting boosters elicit strong immune response

    New vaccine candidates significantly outperform existing Covid jabs at targeting the most prevalent strain

  • Friday, 24 June, 2022
    Covid-19 vaccines
    Sanofi-GSK Covid vaccine found effective against Omicron

    Pharma companies are hoping to catch up with rivals as they report promising trial results for jab

  • Thursday, 23 June, 2022
    Coronavirus treatment
    UK prepares to include over-50s in autumn Covid booster campaign

    Javid says he asked officials to revise previous plans that would exclude under-65s

  • Wednesday, 22 June, 2022
    Medical science
    Poliovirus detected in London sewage samples

    UK health agency investigating possibility of community transmission says risk to public ‘extremely low’

  • Wednesday, 22 June, 2022
    Moderna
    Moderna calls for approval of two-strain Covid vaccine booster

    US biotech group says shot targeting both first strain and Omicron could help avert ‘large rise’ in cases

  • Wednesday, 22 June, 2022
    Covid-19 vaccines
    UK signs £1bn deal with Moderna for new vaccine centre

    Government seeks to secure domestic jab supply and prepare for future pandemics in deal with Boston biotech

  • Wednesday, 22 June, 2022
    Biotech
    Biotechs face ‘funding Sahara’ as easy money runs dry

    Early-stage drugmakers face difficult decisions as public markets turn hostile

  • Tuesday, 21 June, 2022
    Behind the Money podcast28 min listen
    Inside Johnson & Johnson’s bankruptcy two-step

    This legal manoeuvre is setting a new precedent for corporations to evade accountability in America

  • Monday, 20 June, 2022
    Pfizer Inc
    Pfizer buys stake in French vaccine maker Valneva

    US pharma group to pay €90.5mn for 8% in deal that will boost joint Lyme disease programme

  • Saturday, 18 June, 2022
    Covid-19 vaccines
    US CDC recommends Covid vaccines for children under 5

    Children as young as six months old can begin receiving Pfizer or Moderna vaccines as soon as Monday

  • Saturday, 18 June, 2022
    Covid-19 vaccines
    BioNTech chief calls for speedy ruling on Covid vaccines that target latest strains

    ‘Time is ticking’ as studies suggest original Omicron jabs may not offer strong protection against sub-variants

  • Thursday, 16 June, 2022
    Covid-19 vaccines
    WHO set to back use of Covid variant-specific vaccines as third shot

    Recommendation by health agency advisory group marks shift in thinking of global health authorities

  • Thursday, 16 June, 2022
    Medical science
    Charity launches £80mn programme with US partner to address cancer challenges

    Cancer Research UK will eventually spend £295mn with National Cancer Institute on projects to understand and prevent tumour growth

  • Thursday, 16 June, 2022
    Special ReportEurope’s Leading Patent Law Firms
    Nations urged to waive vaccine patents while drugmakers say rules are fair

    Only 1 per cent of the 10bn jabs delivered so far have been in low-income countries

  • Thursday, 16 June, 2022
    Special ReportEurope’s Leading Patent Law Firms
    Ukraine medicine IP waiver becomes ‘matter of life or death’

    Lawyer Olga Gurgula drafted a law to enable the local production of generic drugs for civilians and the military

  • Wednesday, 15 June, 2022
    Covid-19 vaccines
    FDA advisory panel backs Covid-19 vaccines for children under 5

    US prepares to roll out jabs to last age group without access once regulatory approval is received

  • Wednesday, 15 June, 2022
    InterviewOffice of National Drug Control Policy
    US pivots to ‘harm reduction’ after 107,000 overdose deaths last year

    White House drug tsar says marijuana legalisation and safe injection sites will also be reviewed

  • Wednesday, 15 June, 2022
    Pharma bro David Shaw

    Hedgie turned medical researcher notches up a big win

Previous page You are on page 1 Next page

Topics related to Health & pharmaceuticals

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In